Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating dermatitis and preparation method thereof

A composition and drug technology, applied in the field of medicine, can solve the problems of reducing immune defense, rebound effect, etc., and achieve the effect of reducing the inflow of sodium ions

Active Publication Date: 2013-06-12
福州中科伟创生物科技有限公司
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Dermatitis is generally treated with oral antihistamines combined with topical steroids, however topical steroids have well-known side effects: they reduce immune defenses and can induce infections, mainly fungi or candida; treatment should be done gradually ; they should not be used during acute exudates; rebound effects may occur upon discontinuation of treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Weigh the following oil phase component raw materials into the oil phase container to obtain oil phase mixture A: 3 kg of glyceryl monostearate, 3 kg of PEG-100 stearate, 8 kg of liquid paraffin, 0.5 kg Disk 60, 3 kg of stearic acid, 0.5 kg of glycyrrhetinic acid, 2 kg of DC250 simethicone;

[0035] Take the following weights of the water phase component raw materials and throw them into the water phase container to obtain the water phase mixture B: 4 kg of potassium lauryl phosphate, 5 kg of glycerin, 1 kg of diphenhydramine hydrochloride, 55 kg of purified water;

[0036] Weigh the following weights of the active pharmaceutical component raw materials and throw them into the active pharmaceutical component container to obtain the active pharmaceutical component mixture C: 5 kilograms of propylene glycol, 1 kilogram of menthol, 2 kilograms of camphor, and 0.1 kilogram of tetracaine hydrochloride.

[0037] 2) Heat the oil phase mixture A to 80-85°C, heat the water phase...

Embodiment 2

[0043]1) Weigh the following weights of oil phase component raw materials and put them into the oil phase container to obtain oil phase mixture A: 2 kg of glyceryl monostearate, 2 kg of PEG-100 stearate, 6 kg of liquid paraffin, 0.5 kg Span 60, 2 kg of stearic acid, 0.5 kg of glycyrrhetinic acid, 1 kg of DC250 dimethicone;

[0044] The water phase component raw materials of the following weights were weighed and thrown into the water phase container to obtain the water phase mixture B: 4 kg of potassium lauryl phosphate, 3 kg of glycerin, 0.8 kg of diphenhydramine hydrochloride, 55 kg of purified water;

[0045] Take the following weights of the active pharmaceutical component raw materials and throw them into the active pharmaceutical component container to obtain the active pharmaceutical component mixture C: 4 kilograms of propylene glycol, 1 kilogram of menthol, 1 kilogram of camphor, and 0.1 kilogram of tetracaine hydrochloride;

[0046] 2) Heat the oil phase mixture A to...

Embodiment 3

[0052] 1) Weigh the following weights of oil phase component raw materials and put them into the oil phase container to obtain oil phase mixture A: 6 kg of glyceryl monostearate, 6 kg of PEG-100 stearate, 9 kg of liquid paraffin, 1 kg Span 60, 5 kg of stearic acid, 1 kg of glycyrrhetinic acid, 3 kg of DC250 simethicone;

[0053] Weigh the following weights of the water phase component raw materials and throw them into the water phase container to obtain the water phase mixture B: 6 kg of potassium lauryl phosphate, 6 kg of glycerin, 1.2 kg of diphenhydramine hydrochloride, 60 kg of purified water;

[0054] Weigh the following weights of the active pharmaceutical component raw materials and throw them into the active pharmaceutical component container to obtain the active pharmaceutical component mixture C: 6 kilograms of propylene glycol, 2 kilograms of menthol, 2 kilograms of camphor, and 0.1 kilogram of tetracaine hydrochloride;

[0055] 2) Heat the oil phase mixture A to 80...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medical technology, and relates to a pharmaceutical composition for treating dermatitis and a preparation method thereof. The pharmaceutical composition for treating dermatitis is prepared by mixing the following materials: glycerin monostearate, PEG-100 stearate, liquid paraffin, emulsifier 60, stearic acid, glycyrrhetinic acid, DC250dimethicone, lauryl potassium phosphate, glycerol, diphenhydramine hydrochloride, purified water, propylene glycol, menthol, camphor and tetracaine hydrochloride. Based on the common biochemical character and symptom of the dermatitis, diphenhydramine antihistamine is added in the formula, so that the histamine level of inflammatory response on a dermatitis part is reduced. Besides, the licorice extract of glycyrrhetinic acid is added, so that the skin is stimulated to secrete adrenal cortex hormone at the physiological level, and the phenomenon that the cortical hormone level is higher than the physiological level which can be borne by the skin of the human body as the adrenal cortex hormone is externally used and supplemented is avoided.

Description

technical field [0001] The invention relates to the technical field of medicine, and relates to a pharmaceutical composition for treating dermatitis and a preparation method thereof. Background technique [0002] Dermatitis is an abbreviation for a skin inflammatory reaction. The factors causing dermatitis are complex and diverse. According to the cause, it can be divided into contact allergic dermatitis, neurodermatitis, bacterial dermatitis, sunburn dermatitis, drug-induced dermatitis, hormone-dependent dermatitis, etc. Wait. The main symptoms of dermatitis are erythema and rash, severe itching, and skin lesions in the epidermis and dermis of the skin. [0003] Dermatitis is generally treated with oral antihistamines combined with topical steroids, however topical steroids have well-known side effects: they reduce immune defenses and can induce infections, mainly fungi or candida; treatment should be done gradually ; they should not be used during acute exudates; rebound...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/56A61K31/245A61K31/135A61P17/00A61P29/00A61P17/04
Inventor 吴燕斌肖永堂
Owner 福州中科伟创生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com